Henry Schein, Inc. (NASDAQ:HSIC) Stock Holdings Lifted by Wealthspire Advisors LLC

Wealthspire Advisors LLC raised its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 5.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,772 shares of the company’s stock after purchasing an additional 874 shares during the period. Wealthspire Advisors LLC’s holdings in Henry Schein were worth $1,091,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. FMR LLC raised its position in Henry Schein by 7.8% during the third quarter. FMR LLC now owns 3,280,890 shares of the company’s stock valued at $239,177,000 after acquiring an additional 237,888 shares in the last quarter. Southpoint Capital Advisors LP increased its stake in shares of Henry Schein by 30.0% during the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock worth $189,540,000 after purchasing an additional 600,000 shares during the last quarter. Nuance Investments LLC raised its holdings in shares of Henry Schein by 22.3% during the 3rd quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock valued at $166,072,000 after purchasing an additional 414,748 shares in the last quarter. Clarkston Capital Partners LLC lifted its stake in shares of Henry Schein by 5.4% in the 3rd quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company’s stock valued at $101,900,000 after purchasing an additional 71,560 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Henry Schein by 0.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,175,061 shares of the company’s stock worth $85,662,000 after purchasing an additional 6,184 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Barrington Research raised their target price on Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, January 30th. Mizuho began coverage on Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 target price for the company. Wells Fargo & Company started coverage on Henry Schein in a report on Friday, February 14th. They set an “equal weight” rating and a $80.00 price target on the stock. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and upped their price objective for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Henry Schein presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.09.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $77.64 on Tuesday. The firm’s 50-day moving average is $74.19 and its 200-day moving average is $72.38. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. Henry Schein, Inc. has a 52-week low of $63.67 and a 52-week high of $82.63. The company has a market cap of $9.68 billion, a price-to-earnings ratio of 31.95, a PEG ratio of 2.13 and a beta of 0.91.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.